BEIJING (Reuters) – The health government of the Republic of Peru approved a Phase 3 clinical trial for a COVID-19 vaccine developed through the National Biotech Group of China (CNBG), the company said Thursday on the Chinese social media platform Weibo.
The experimental CNBG vaccine, a unit of the public pharmaceutical company China National Pharmaceutical Group (Sinopharm), has already entered Phase 3 in the United Arab Emirates.
Phase 3 trials, involving several thousand participants, allow researchers to gather knowledge about the effectiveness of prospective vaccines for final regulatory approvals.
(This story went to the right type of spelling)
Reporting through Roxanne Liu and Tony Munroe in Beijing; Editing via Shri Navaratnam
All quotes were delayed for at least 15 minutes. See here for a complete list of transactions and delays.
© 2020 Reuters. All rights are reserved.